GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Artivion Inc (NYSE:AORT) » Definitions » Debt-to-EBITDA
中文

Artivion (Artivion) Debt-to-EBITDA : 7.81 (As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Artivion Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Artivion's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $5.4 Mil. Artivion's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $352.9 Mil. Artivion's annualized EBITDA for the quarter that ended in Dec. 2023 was $45.9 Mil. Artivion's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 7.81.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Artivion's Debt-to-EBITDA or its related term are showing as below:

AORT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.4   Med: 12.91   Max: 15.68
Current: 13.38

During the past 13 years, the highest Debt-to-EBITDA Ratio of Artivion was 15.68. The lowest was 2.40. And the median was 12.91.

AORT's Debt-to-EBITDA is ranked worse than
96.74% of 430 companies
in the Medical Devices & Instruments industry
Industry Median: 1.225 vs AORT: 13.38

Artivion Debt-to-EBITDA Historical Data

The historical data trend for Artivion's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artivion Debt-to-EBITDA Chart

Artivion Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.04 15.68 13.91 13.89 13.38

Artivion Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.34 30.54 9.38 30.37 7.81

Competitive Comparison of Artivion's Debt-to-EBITDA

For the Medical Devices subindustry, Artivion's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Artivion's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Artivion's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Artivion's Debt-to-EBITDA falls into.



Artivion Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Artivion's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(5.428 + 352.913) / 26.789
=13.38

Artivion's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(5.428 + 352.913) / 45.876
=7.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Artivion  (NYSE:AORT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Artivion Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Artivion's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Artivion (Artivion) Business Description

Traded in Other Exchanges
Address
1655 Roberts Boulevard North West, Kennesaw, GA, USA, 30144
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others.
Executives
Jean F Holloway officer: VP, General Counsel C/O ARTIVION INC, 1655 ROBERTS BLVD, KENNESAW GA 30144
John E Davis officer: Senior VP, Global Sales 1655 ROBERTS BLVD., NW, KENNESAW GA 30144
Amy Horton officer: Chief Accounting Officer C/O CRYOLIFE, INC., 1655 ROBERTS BLVD., NW, KENNESAW GA 30144
Florian Tyrs officer: VP, Global Operations IM SOELLER 3, BALINGEN 2M 72336
Robert C Thomson officer: VP Research & Development 33 HABERSHAM COVE DRIVE, NW, ATLANTA GA 30305
Matthew A Getz officer: VP, Human Resources 1655 ROBERTS BLVD NW, KENNESAW GA 30144
Dennis B Maier officer: Vice President, Operations 1655 ROBERTS BLVD, NW, KENNESAW GA 30144
Rochelle L. Maney officer: VP, Quality 1655 ROBERTS BLVD, NW, KENNESAW GA 30144
James P Mackin officer: President & CEO ARTIVION, INC., 1655 ROBERTS BLVD, NW, KENNESAW GA 30144
Marshall S. Stanton officer: SVP, Clinical & MD Affair 1655 ROBERTS BLVD, NW, KENNESAW GA 30144
Andrew M Green officer: VP Regulatory ARTIVION INC, 1655 ROBERTS BLVD, KENNESAW GA 30144
David Ashley Lee officer: Executive VP, COO & CFO C/O CRYOLIFE INC, 1655 ROBERTS BLVD NW, KENNESAW GA 30144
Elizabeth A Hoff director 2701 WESTHEIMER ROAD, UNIT 1-E, HOUSTON TX 77098
Anthony B. Semedo director 3288 HARRISON GRADE ROAD, SEBASTOPOL CA 95472
Ronald D Mccall director C/O CRYOLIFE, INC., 1655 ROBERTS BOULEVARD, NW, KENNESAW GA 30144